Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [9532]

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Discovering selective anticancer drugs: succeeding slowly is better than...

Professor Hilary Calvert - UCL Cancer Institute, London, UK

Discovering selective anticancer drugs: succeeding slowly is better than failing fast ( Professor Hilary Calvert - UCL Cancer Institute, London, UK )

Putting adoptive T cell therapy on the path to regulatory approval

Prof Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Putting adoptive T cell therapy on the path to regulatory approval ( Prof Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Using Hsp90 inhibitors in the clinic: what have we learned?

Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom

Using Hsp90 inhibitors in the clinic: what have we learned? ( Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom )

Radiogenomic evaluation of tumour response to targeted agents

Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA

Radiogenomic evaluation of tumour response to targeted agents ( Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA )

New drugs and targets in haematological malignancies

Dr Renier Brentjens - Memorial Sloan Kettering Cancer Center, New York, USA

New drugs and targets in haematological malignancies ( Dr Renier Brentjens - Memorial Sloan Kettering Cancer Center, New York, USA )

Mutant-specific kinase inhibitors and TAT highlights

Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France

Mutant-specific kinase inhibitors and TAT highlights ( Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France )

Drugging the cancer genome to overcome drug resistance

Prof Paul Workman - Institute of Cancer Research, UK

Drugging the cancer genome to overcome drug resistance ( Prof Paul Workman - Institute of Cancer Research, UK )

ecancermedicalscience editor's choice for February 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for February 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Effectiveness of adjuvant chemotherapy on patients with bladder cancer

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Effectiveness of adjuvant chemotherapy on patients with bladder cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

ASCO GU 2015 news roundup

Peter Goodwin - ecancer correspondent, London, UK

ASCO GU 2015 news roundup ( Peter Goodwin - ecancer correspondent, London, UK )

Taxane response in prostate cancer may not be influenced by androgen receptor...

Dr Emmanuel Antonarakis - Johns Hopkins School of Medicine, Baltimore, USA

Taxane response in prostate cancer may not be influenced by androgen receptor variations ( Dr Emmanuel Antonarakis - Johns Hopkins School of Medicine, Baltimore, USA )

More from ecancer